Intrinsiqq
Zhengye Biotechnology Holding Ltd. logo

Zhengye Biotechnology Holding Ltd.

ZYBT

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap¥434M
EPS-¥1.76
P/E-0.78
P/FCF617.68
EV/EBITDA-6.70
FCF Yield0.2%
Div. Yield–
Net Debt/FCF33.0x
Zhengye Biotechnology Holding Ltd. intrinsic value
52-Week Range
$0.65$2.85

Profitability & Returns

Revenue (TTM)

¥116M

▼ -37.6% YoY

Net Income (TTM)

-¥83M

▼ -715.9% YoY

Op. Margin

-58.66%

▼ -67.9pp YoY

ROIC

-13.14%

▼ -16.8pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

¥703K

▼ -94.7% YoY

Op. Cash Flow (TTM)

¥13M

▼ -67.5% YoY

Net Debt

¥23M

Cash & Equiv.

¥52M

3Y CAGR: -23.5%

Continue Research

Peers

Drug Manufacturers - Specialty & Generic · Pick stocks to compare with ZYBT

CompareIntrinsic value
MAK.XETRMaternus-Kliniken Aktiengesellschaft
€0.82-3.51%61
CONTX.XOSLContextVision AB
kr 4.69+5.87%36
AZT.XOSLArcticZymes Technologies ASA
€1.97-4.15%23
MDXHMDxHealth SA
$0.15-3.21%30
REG1V.XHELRevenio Group Oyj
€10.32+0.10%51
SEZI.XSTOSenzime AB
€0.29+3.24%40
GENO.XSTOGenovis AB
€1.86-1.17%53
TALEA.XMILTalea Group S.p.A.
No recent price33

Zhengye Biotechnology Holding (ZYBT) in four numbers

Fair value (revenue)
$0.94
Price $1.38 is 47% above it.
Intrinsic Value
Quality score
9/100
Best check: share count change, 3.3%. Weakest: return on capital, -13.1%.
Quality
Dividend
None
Last paid CNY 0.34 a share in fiscal 2024.
Dividends
P/E
-0.78
Negative: a loss over the last twelve months. Price to free cash flow 617.68.
Financials

Questions about Zhengye Biotechnology Holding

Is Zhengye Biotechnology Holding (ZYBT) overvalued?

At $1.38, Zhengye Biotechnology Holding's price is 47% above the $0.94 a share fair value that Intrinsiqq's calculator gets from its revenue. It trades at 617.68 times free cash flow. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.

What is Zhengye Biotechnology Holding's fair value?

Intrinsiqq's calculator puts Zhengye Biotechnology Holding's fair value at $0.94 a share. It grows revenue per share 0% a year for 5 years, applies an exit P/S of 4.1, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $0.71. Every input can be changed on the Intrinsic Value tab.

Is Zhengye Biotechnology Holding a high-quality business?

Zhengye Biotechnology Holding scores 9 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 7 checks computed from company filings. Its best check is share count change at 3.3%, and its weakest is return on capital at -13.1%. The Quality tab shows every check against its target.

Does Zhengye Biotechnology Holding (ZYBT) pay a dividend?

No. Zhengye Biotechnology Holding (ZYBT) paid CNY 0.34 per share in fiscal 2024 and has paid nothing in the last twelve months. The Dividends tab has the full payment history.

Source: company filings. Price: last close 5 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing ZYBT

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.